A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten.
Zeynep YukselenArvind Kumar Venkataramana RajuPramukh Arun KumarAditi UjjawalMahati DasariShreyash ParajuliMichael NakhlaKannu BansalSarju GanatraSourbha S DaniPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2024)
The results of our study were consistent with the safety data of clinical trials, including reduced ejection fraction, atrial fibrillation, dyspnea, and syncope. We also found potential new and unexpected ADR signals, such as urinary tract infection, gout, and peripheral edema.